DUOPHARMA BIOTECH BERHAD
KLSE (MYR): DPHARMA (7148)
You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!
Last Price
1.25
Today's Change
-0.01 (0.79%)
Day's Change
1.24 - 1.26
Trading Volume
348,000
Financial
Market Cap
Market Cap
1,202 Million
NOSH
962 Million
Latest Quarter
Latest Quarter
30-Sep-2024 [#3]
Announcement Date
08-Nov-2024
Next Quarter
31-Dec-2024
Est. Ann. Date
22-Feb-2025
Est. Ann. Due Date
01-Mar-2025
QoQ | YoY
-6.56% | 73.86%
T4Q Result
Revenue | NP to SH
787,525.000 | 56,063.000
RPS | P/RPS
81.87 Cent | 1.53
EPS | P/E | EY
5.83 Cent | 21.45 | 4.66%
DPS | DY | Payout %
2.80 Cent | 2.24% | 48.04%
NAPS | P/NAPS
0.72 | 1.74
QoQ | YoY
13.4% | -8.55%
NP Margin | ROE
7.12% | 8.09%
F.Y. | Ann. Date
30-Sep-2024 | 08-Nov-2024
Latest Audited Result
Latest Audited Result
31-Dec-2023
Announcement Date
26-Apr-2024
Next Audited Result
31-Dec-2024
Est. Ann. Date
26-Apr-2025
Est. Ann. Due Date
29-Jun-2025
Annual (Unaudited)
Revenue | NP to SH
704,727.000 | 52,645.000
RPS | P/RPS
73.26 Cent | 1.71
EPS | P/E | EY
5.49 Cent | 22.84 | 4.38%
DPS | DY | Payout %
2.30 Cent | 1.84% | 42.03%
NAPS | P/NAPS
0.71 | 1.76
YoY
-24.91%
NP Margin | ROE
7.47% | 7.71%
F.Y. | Ann. Date
31-Dec-2023 | 22-Feb-2024
Annualized Result
Revenue | NP to SH
826,698.666 | 63,416.000
RPS | P/RPS
85.94 Cent | 1.45
EPS | P/E | EY
6.59 Cent | 18.96 | 5.27%
DPS | DY | Payout %
-
NAPS | P/NAPS
-
QoQ | YoY
-0.81% | 7.75%
NP Margin | ROE
7.67% | 9.16%
F.Y. | Ann. Date
30-Sep-2024 | 08-Nov-2024
Business Process
| Trailing 4 Quarters | Trailing 8 Quarters | |||
|---|---|---|---|---|
| Available Quarters | 4 Quarters | 8 Quarters | ||
| Continuous Quarters Of Revenue Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Total Positive Profit Years | 4 / 4 | 100.00% | 8 / 8 | 100.00% |
| Continuous Quarters Of Positive Profit | 4 / 4 | 100.00% | 8 / 8 | 100.00% |
| Continuous Quarters Of Profit Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Continuous Quarters Of Adjusted EPS Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Total Dividend Years | 2 / 4 | 50.00% | 4 / 8 | 50.00% |
| Continuous Quarters Of Dividend | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Continuous Quarters Of Dividend Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Continuous Quarters Of Adjusted Dps Growth | 0 / 4 | 0.00% | 0 / 8 | 0.00% |
| Average ROE | 2.04% | 2.17% | ||
| Average Net Profit Margin | 7.03% | 7.93% | ||
| Last 5 Financial Years | Last 10 Financial Years | |||
|---|---|---|---|---|
| Available Years | 5 Years | 10 Years | ||
| Continuous Quarters Of Revenue Growth | 3 / 5 | 60.00% | 3 / 10 | 30.00% |
| Total Positive Profit Years | 5 / 5 | 100.00% | 10 / 10 | 100.00% |
| Continuous Quarters Of Positive Profit | 5 / 5 | 100.00% | 10 / 10 | 100.00% |
| Continuous Quarters Of Profit Growth | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
| Continuous Quarters Of Adjusted EPS Growth | 0 / 5 | 0.00% | 0 / 10 | 0.00% |
| Total Dividend Years | 5 / 5 | 100.00% | 10 / 10 | 100.00% |
| Continuous Quarters Of Dividend | 5 / 5 | 100.00% | 10 / 10 | 100.00% |
| Continuous Quarters Of Dividend Growth | 2 / 5 | 40.00% | 2 / 10 | 20.00% |
| Continuous Quarters Of Adjusted Dps Growth | 2 / 5 | 40.00% | 2 / 10 | 20.00% |
| Average ROE | 9.72% | 10.59% | ||
| Average Net Profit Margin | 9.54% | 11.95% | ||
Key Result
| T4Q | Annualized | Annual (Unaudited) | Last 10 FY Average | Last 5 FY Average | |
|---|---|---|---|---|---|
| Revenue | 787,525 | 826,698 | 704,727 | 491,427 | 637,396 |
| NP to SH | 56,063 | 63,416 | 52,645 | 49,361 | 60,464 |
| Dividend | 26,934 | 12,825 | 22,124 | 27,228 | 30,503 |
| Adjusted EPS | 5.83 | 6.59 | 5.49 | 5.13 | 6.29 |
| Adjusted DPS | 2.80 | 1.33 | 2.30 | 2.83 | 3.17 |
NP to SH = Net Profit Attributable to Shareholder, EPS = Earning Per Share, DPS = Dividend Per Share
All figures in '000 unless specified.
EPS & DPS's figures in Cent.
Growth
| LQ QoQ | LQ YoY | CQ YoY | LQ vs Average of T4Q | LQ vs Average of T8Q | |
|---|---|---|---|---|---|
| Revenue | -4.39% | 23.34% | 15.41% | 6.02% | 13.08% |
| NP to Owner | -6.56% | 73.86% | 7.75% | 11.27% | 6.30% |
| Dividend | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% |
| Adjusted EPS | -6.36% | 74.19% | 7.16% | 11.34% | 6.31% |
| Adjusted DPS | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% |
LQ = Latest Quarter, CQ = Cumulative Quarter, T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, QoQ = Quarter on Quarter, YoY = Year on Year
| T4Q vs LFY | T4Q vs AL5FY | T4Q vs AL10FY | AQR vs LFY | AQR vs AL5FY | AQR vs AL10FY | LFY YoY | LFY vs AL5FY | LFY vs AL10FY | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 11.75% | 23.55% | 60.25% | 17.31% | 29.70% | 68.22% | 1.15% | 10.56% | 43.40% |
| NP to Owner | 6.49% | -7.28% | 13.58% | 20.46% | 4.88% | 28.47% | -24.91% | -12.93% | 6.65% |
| Dividend | 21.74% | -11.70% | -1.08% | -42.03% | -57.95% | -52.90% | 1.02% | -27.47% | -18.74% |
| Adjusted EPS | 6.19% | -7.30% | 13.57% | 20.04% | 4.78% | 28.38% | -24.68% | -12.71% | 6.95% |
| Adjusted DPS | 21.74% | -11.70% | -1.08% | -42.17% | -58.06% | -53.01% | 1.02% | -27.47% | -18.74% |
T4Q = Trailing 4 Quarters, T8Q = Trailing 8 Quarters, AL5FY = Average of Last 5 Financial Years, AL10FY = Average of Last 10 Financial Years, LFY = Latest Financial Year AQR = Annualized Quarter Result, YoY = Year on Year
Discussions
13 people like this. Showing 50 of 12,449 comments
Managed and operated by white haired people sitting in wheel chairs and using walking sticks. Most have prostate problems, waking few times at night to urinate. Some are waiting for stairways to Heavens........HOW COULD COMPANY BE AGGRESSIVE???
2023-10-08 13:10
3Q23 profits down 45% YoY....current BOD is a team of silver haired centennials in wheelchairs. Raising 2 Billion bonds for retirement benefits?
BOD too aggressive is bad, weak BOD is also bad.......take your pick.
2023-11-10 12:07
Pharma is dying, yet this ctnr with Management in wheelchairs cannot take advantage.
2023-12-02 09:04
This is just reaction to Covid case spike, after that fall back down. Nothing new and exciting on the horizon for pharma in the coming months especially when Pharmaniaga still in the dump and government cutting back on spending.
2023-12-15 16:03
Hope this collaboration can bring good revenue to the company for Fy2024 and so on
https://theedgemalaysia.com/node/692365
2024-01-15 17:14
Duopharma Biotech Bhd is likely to see a recovery in its consumer healthcare (CHC) segment, while sales to the government sector is also expected to increase in 2024.
https://www.thestar.com.my/business/business-news/2024/01/26/duopharma-earnings-set-to-improve-this-year
2024-01-30 17:36
Duopharma Biotech Clinches MYR578 million Supply Deals
https://www.tradingview.com/news/mtnewswires.com:20240501:G2361746:0/
2024-05-02 09:21
Yuhoo!!! Finally Duo making big move. 1.40 seems reasonable figure to relief breath.
2024-05-02 19:09
Ayo!!! What has 600m contract do to the Duo's share price??? Sometime the illogical happen.....
2024-05-04 18:39
Keep & follow TP from OSK
https://klse.i3investor.com/web/pricetarget/research/71461
2024-05-28 14:28
That is 1-year low price for Dpharma dude
fruitcake
1.10 please
19 hours ago
2024-06-14 11:03
Haha unfortunately i'm closing my position with Dpharma, feels like watching paint dry. Anyways good luck guys.
2024-06-26 11:32
I think they have. https://www.freemalaysiatoday.com/category/nation/2016/01/28/viagra-no-longer-hard-to-get/
2024-07-04 11:46
Duopharma Biotech 2Q net profit up 33%, pays one sen dividend 🔥
https://theedgemalaysia.com/node/722957
2024-08-16 11:40
DPHARMA: Reaping the Rewards of a Strong Ringgit
https://klse.i3investor.com/web/blog/detail/bestStocks/2024-09-26-story-h470048636-DPHARMA_Reaping_the_Rewards_of_a_Strong_Ringgit
2 months ago
Post a Comment
Featured Posts
Latest Videos
Apps
Top Articles
1
Stock Market Enthusiast
Top 3 AI/Data Center Newsflow for the 3rd Week of December - #TENAGA, #YTL, #YTLPOWER
2
Rakuten Trade Research Reports
3
save malaysia!
4
Good Articles to Share
5
Good Articles to Share
6
Good Articles to Share
Gaza ceasefire deal 'closer than ever', says Hamas and two allies
7
Good Articles to Share
Ryan Serhant makes bold pitch to fix the housing ‘affordability crisis’
8
Good Articles to Share
#
Stock
Score
Daily Stocks
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Featured Advertisers / Partners
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
stevenckheng
noob company slowly moving a way from pharmaceutical
2023-09-06 20:25